source
- Incyte to buy blood disorder drug in possibly $2B dealAcquiring Vega Therapeutics, an offshoot of "hub-and-spoke" biotech Star Therapeutics, would give Incyte a medicine that’s in late-stage testing and designed to control bleeding.BioPharma Dive · 1mo ago↗ source
- J&J to acquire Firefly, maker of ‘degrader’ antibody drugs, for $1BThe buyout hands J&J a technology that merges elements of two popular drugmaking methods: protein degraders and antibody-drug conjugates.BioPharma Dive · 1mo ago↗ source
- Treeline to go public via reverse merger with Standard BioToolsTreeline Biosciences has shared plans to debut on public markets through a reverse merger with Standard BioTools in a move that should give the company a cash runway through 2029. The